Integral Health Asset Management LLC Has $2.49 Million Stock Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

Integral Health Asset Management LLC lifted its holdings in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 50.0% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 450,000 shares of the company's stock after acquiring an additional 150,000 shares during the period. Integral Health Asset Management LLC owned approximately 0.53% of Terns Pharmaceuticals worth $2,493,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. Invesco Ltd. lifted its position in shares of Terns Pharmaceuticals by 13.3% during the 4th quarter. Invesco Ltd. now owns 23,400 shares of the company's stock valued at $130,000 after buying an additional 2,753 shares in the last quarter. Corebridge Financial Inc. increased its stake in shares of Terns Pharmaceuticals by 13.5% in the 4th quarter. Corebridge Financial Inc. now owns 34,951 shares of the company's stock worth $194,000 after acquiring an additional 4,169 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Terns Pharmaceuticals by 33.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,010 shares of the company's stock worth $100,000 after purchasing an additional 4,475 shares during the last quarter. MetLife Investment Management LLC increased its position in shares of Terns Pharmaceuticals by 27.7% during the 4th quarter. MetLife Investment Management LLC now owns 43,760 shares of the company's stock worth $242,000 after purchasing an additional 9,500 shares during the last quarter. Finally, SG Americas Securities LLC increased its position in shares of Terns Pharmaceuticals by 40.0% during the 4th quarter. SG Americas Securities LLC now owns 33,333 shares of the company's stock worth $185,000 after purchasing an additional 9,523 shares during the last quarter. Hedge funds and other institutional investors own 98.26% of the company's stock.

Analyst Upgrades and Downgrades

TERN has been the subject of several recent research reports. BMO Capital Markets decreased their price objective on Terns Pharmaceuticals from $26.00 to $15.00 and set an "outperform" rating for the company in a research note on Tuesday. JMP Securities reaffirmed a "market outperform" rating and set a $20.00 price target on shares of Terns Pharmaceuticals in a research report on Monday, April 21st. Finally, William Blair reaffirmed a "market perform" rating on shares of Terns Pharmaceuticals in a research report on Friday, March 21st. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $15.63.

Terns Pharmaceuticals Trading Up 3.2%

NASDAQ:TERN traded up $0.09 on Friday, hitting $2.88. 747,351 shares of the stock were exchanged, compared to its average volume of 1,535,356. Terns Pharmaceuticals, Inc. has a fifty-two week low of $1.87 and a fifty-two week high of $11.40. The stock has a market cap of $251.53 million, a PE ratio of -2.44 and a beta of -0.16. The stock has a fifty day moving average of $2.84 and a 200-day moving average of $4.46.

Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.03. As a group, analysts predict that Terns Pharmaceuticals, Inc. will post -1.19 earnings per share for the current year.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.